Department of Clinical Pharmacy and Pharmacology, Medical Centre Leeuwarden, Leeuwarden, The Netherlands.
Department PharmacoTherapy, Epidemiology and Economy, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.
Clin Exp Allergy. 2022 Nov;52(11):1247-1263. doi: 10.1111/cea.14212. Epub 2022 Aug 23.
This review presents an overview of the available literature regarding intranasal corticosteroids (INCs) for the treatment of allergic rhinitis (AR). Various treatment options exist for AR including INCs, antihistamines and leucotriene antagonists. INCs are considered to be the most effective therapy for moderate-to-severe AR, as they are effective against nasal and ocular symptoms and improve quality of life. Their safety has been widely observed. INCs are effective and safe for short-term use. Local adverse events are observed but generally well-tolerated. The occurrence of (serious) systemic adverse events is unlikely but cannot be ruled out. There is a lack of long-term safety data. INC may cause serious eye complications. The risk of INCs on the hypothalamic-pituitary-adrenal axis, on bone mineral density reduction or osteoporosis and on growth in children, should be considered during treatment. Pharmacological characteristics of INCs (e.g. the mode of action and pharmacokinetics) are well known and described. We sought to gain insight into whether specific properties affect the efficacy and safety of INCs, including nasal particle deposition, which the administration technique affects. However, advances are lacking regarding the improved understanding of the effect of particle deposition on efficacy and safety and the effect of the administration technique. This review emphasizes the gaps in knowledge regarding this subject. Advances in research and health care are necessary to improve care for patients with AR.
这篇综述介绍了鼻腔内皮质类固醇(INCs)治疗过敏性鼻炎(AR)的现有文献概述。AR 的各种治疗选择包括 INCs、抗组胺药和白三烯拮抗剂。INCs 被认为是中重度 AR 的最有效治疗方法,因为它们对鼻腔和眼部症状均有效,并能改善生活质量。其安全性已得到广泛观察。INCs 短期使用有效且安全。局部不良事件虽有发生,但通常可耐受。(严重)全身性不良事件的发生不太可能,但不能排除。缺乏长期安全性数据。INC 可能引起严重眼部并发症。在治疗过程中应考虑 INCs 对下丘脑-垂体-肾上腺轴、骨矿物质密度降低或骨质疏松症以及儿童生长的影响。INCs 的药理学特性(如作用模式和药代动力学)是众所周知的,并已作描述。我们试图深入了解是否特定特性会影响 INCs 的疗效和安全性,包括鼻腔颗粒沉积,而这会受给药技术影响。然而,在改善对颗粒沉积对疗效和安全性的影响以及给药技术的影响的理解方面,进展仍有限。这篇综述强调了这一主题的知识空白。需要在研究和医疗保健方面取得进展,以改善 AR 患者的护理。